Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Serious outcomes
Cases
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 vitamin A studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 55% 5 15,863 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 66% 2 469 Mortality 42% 2 207 Ventilation 71% 0 120 ICU admission 61% 0 120 Progression 48% 1 140 Cases 64% 2 15,436 Peer-reviewed 75% 1 300 Prophylaxis 64% 2 15,436 Early 79% 2 240 Late -282% 1 27 Vitamin A for COVID-19 c19early.com/va Dec 5, 2021 Favors vitamin A Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.07-0.61] 4/120 20/120 79% improvement Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Improvement, RR [CI] Treatment Control Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 64% 0.36 [0.24-0.54] 21/188 510/15,248 64% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 = 0.00; I​2 = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 55% 0.45 [0.20-1.02] 42/381 587/15,482 55% improvement 7 vitamin A COVID-19 studies c19early.com/va Dec 5, 2021 Tau​2 = 0.88; I​2 = 78.4%; Z = 1.91 Effect extraction pre-specified Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 67% 0.33 [0.07-1.57] 2/50 6/50 67% improvement Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 64% 0.36 [0.23-0.54] 20/97 65/112 64% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 = 0.00; I​2 = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 66% 0.34 [0.24-0.48] 30/210 124/259 66% improvement 4 vitamin A COVID-19 studies after exclusions c19early.com/va Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 6.01 Effect extraction pre-specified Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] 2/70 14/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 86% 0.14 [0.03-0.61] 2/70 14/70 86% improvement Sarohan -282% 3.83 [1.58-9.24] 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Tepasse 70% 0.30 [0.07-0.97] 4/29 5/11 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Sufficiency 70% 0.30 [0.07-0.97] 4/29 5/11 70% improvement All studies 42% 0.58 [0.07-4.59] 15/109 23/98 42% improvement 3 vitamin A COVID-19 mortality results c19early.com/va Dec 5, 2021 Tau​2 = 2.99; I​2 = 90.1%; Z = 0.52 Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tomasa-Irriguible 71% 0.29 [0.10-0.67] 4/34 48/86 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Sufficiency 71% 0.29 [0.10-0.67] 4/34 48/86 71% improvement All studies 71% 0.29 [0.11-0.73] 4/34 48/86 71% improvement 1 vitamin A COVID-19 mechanical ventilation result c19early.com/va Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.61 Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tomasa-Irriguible 61% 0.39 [0.15-0.80] 6/34 54/86 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Sufficiency 61% 0.39 [0.15-0.80] 6/34 54/86 61% improvement All studies 61% 0.39 [0.18-0.81] 6/34 54/86 61% improvement 1 vitamin A COVID-19 ICU result c19early.com/va Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.50 Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Tau​2 = 0.00; I​2 = 0.0% Early treatment 79% 0.21 [0.07-0.61] 4/120 20/120 79% improvement Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -282% 3.83 [1.58-9.24] 9/10 4/17 -282% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 = 0.00; I​2 = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 54% 0.46 [0.13-1.65] 21/193 77/234 54% improvement 5 vitamin A COVID-19 serious outcomes c19early.com/va Dec 5, 2021 Tau​2 = 1.75; I​2 = 84.1%; Z = 1.19 Effect extraction pre-specified Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 64% 0.36 [0.23-0.54] 20/97 65/112 Improvement, RR [CI] Treatment Control Holt 56% 0.44 [0.06-2.96] 1/91 445/15,136 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 64% 0.36 [0.24-0.54] 21/188 510/15,248 64% improvement All studies 64% 0.36 [0.24-0.54] 21/188 510/15,248 64% improvement 2 vitamin A COVID-19 case results c19early.com/va Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 4.88 Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 86% 0.14 [0.03-0.61] 2/70 14/70 86% improvement Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Improvement, RR [CI] Treatment Control Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tau​2 = 0.00; I​2 = 0.0% Sufficiency 71% 0.29 [0.14-0.60] 8/63 53/97 71% improvement All studies 75% 0.25 [0.13-0.48] 10/133 67/167 75% improvement 3 vitamin A COVID-19 peer reviewed trials c19early.com/va Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 4.17 Effect extraction pre-specified Favors vitamin A Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Tomasa-Irriguible 71% 0.29 [0.10-0.67] ventilation 4/34 48/86 Tomasa-Irriguible 61% 0.39 [0.15-0.80] ICU 6/34 54/86 Tepasse 70% 0.30 [0.07-0.97] death 4/29 5/11 Tepasse 45% 0.55 [0.16-1.00] progression 13/29 9/11 vitamin A COVID-19 outcomes c19early.com/va Dec 5, 2021 Favors vitamin A Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit